This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (311) JMIR Theme Issue: COVID-19 Special Issue (2452)

Published on in Vol 9, No 12 (2020): December

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/23830, first published .
Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial

Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial

Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial

Authors of this article:

Junko Terada-Hirashima1 Author Orcid Image ;   Manabu Suzuki1 Author Orcid Image ;   Yukari Uemura2 Author Orcid Image ;   Masayuki Hojo1 Author Orcid Image ;   Ayako Mikami2 Author Orcid Image ;   Wataru Sugiura2 Author Orcid Image ;   Norio Ohmagari3 Author Orcid Image ;   Haruhito Sugiyama1 Author Orcid Image
Article Authors Cited by (15) Tweetations (13) Metrics

Journals

  1. Hojo M, Terada-Hirashima J, Sugiyama H. COVID-19 and bronchial asthma: current perspectives. Global Health & Medicine 2021;3(2):67 View
  2. SUGIURA W. 5．Confronting COVID-19： Current Issues of SARS-CoV-2 Therapeutic Drug/Vaccine Development. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku 2021;26(1):91 View
  3. Chavda V, Vora L, Pandya A, Patravale V. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discovery Today 2021;26(11):2619 View
  4. Song J, Yoon J, Seo Y, Lee J, Eom J, Lee J, Choi W, Lee E, Choi Y, Hyun H, Seong H, Noh J, Cheong H, Kim W. Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. Journal of Clinical Medicine 2021;10(16):3545 View
  5. Bafadhel M, Faner R, Taillé C, Russell R, Welte T, Barnes P, Agustí A. Inhaled corticosteroids for the treatment of COVID-19. European Respiratory Review 2022;31(166):220099 View
  6. Terada J, Fujita R, Kawahara T, Hirasawa Y, Kinoshita T, Takeshita Y, Isaka Y, Kinouchi T, Tajima H, Tada Y, Tsushima K. Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial. eClinicalMedicine 2022;49:101484 View
  7. Kitahara Y, Nakamura R, Okimoto M, Miwata K, Ito N, Takafuta T. Concurrent coronavirus disease 2019 and primary syphilis in a young man: A rare case report. Journal of Infection and Chemotherapy 2022;28(11):1552 View
  8. Griesel M, Wagner C, Mikolajewska A, Stegemann M, Fichtner F, Metzendorf M, Nair A, Daniel J, Fischer A, Skoetz N. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 2022;2022(3) View
  9. Ehtezazi T. The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered- Dose Inhaler in the Treatment of COVID-19 Patients. Recent Advances in Drug Delivery and Formulation 2022;16(1):3 View
  10. Mortezaei Z, Mohammadian A, Tavallaei M. Variations of SARS-CoV-2 in the Iranian population and candidate putative drug-like compounds to inhibit the mutated proteins. Heliyon 2022;8(7):e09910 View
  11. El-Saber Batiha G, Al-Gareeb A, Saad H, Al-kuraishy H. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology 2022;30(4):1189 View
  12. Sugiyama H. 2) COVID-19: Clinician's Point of View-analysis of Large-scale Japanese Registry. Nihon Naika Gakkai Zasshi 2021;110(9):2089 View
  13. KARAMPELA I, VALLIANOU N, TSILINGIRIS D, CHRISTODOULATOS G, MUSCOGIURI G, BARREA L, VITALE G, DALAMAGA M. Could inhaled corticosteroids be the game changers in the prevention of severe COVID-19? A review of current evidence. Panminerva Medica 2022;64(3) View
  14. Terada-Hirashima J, Suzuki M, Tsujimoto Y, Hamamoto Y, Uemura Y, Tsushima K, Inoue H, Komatsu S, Saito Z, Tsuzuki R, Okamoto M, To Y, Moriya K, Yoshizawa S, Tanaka M, Muto T, Mikami A, Takasaki J, Izumi S, Ohmagari N, Hojo M, Sugiura W, Sugiyama H. Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: A randomized trial. Drug Discoveries & Therapeutics 2022;16(5):225 View
  15. Mikami A, Terada-Hirashima J, Tokita D, Sugiura W. Clinical trial experience in Japan and future issues in developing drugs to treat COVID-19. Global Health & Medicine 2023;5(2):85 View